Medical Advocates
Dolutegravir
(S/GSK1349572) |
Last
Update:
March 10, 2012
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader |
March 2012
2012 CROI Citations
|
-
POSTER
Antiviral Activity in vitro of the INI, Dolutegravir, against
Raltegravir-resistant HIV-2 Mutants
Mi Kobayashi, T Seki T
Yoshinaga, et al
PDF Poster
Abstract
|
Journal Citations
|
|
|
|
|
|
|
Journal Papers, Abstracts, and Commentaries
|
-
Dolutegravir for the treatment of HIV.
Katlama C, Murphy R.Expert Opin Investig Drugs.
2012 Mar
2
-
Characterization of the R263K mutation in HIV-1 integrase
that confers low-level resistance
to the second-generation integrase strand transfer inhibitor
Dolutegravir.
Quashie PK, Mesplède T, Han Y,
et alJ
Virol. 2011 Dec 28.
-
A WEEK-IN-REVIEW FEATURED REPORT
Implications of integrase inhibitors for HIV-infected
transplantation recipients:
Raltegravir and dolutegravir (S/GSK 1349572).
Waki K, Sugawara Y.
Biosci Trends. 2011
Oct;5(5):189-91.
Abstract
-
Once daily dolutegravir (S/GSK1349572) in combination
therapy in antiretroviral-naive adults with HIV:
planned interim 48 week results from SPRING-1, a
dose-ranging, randomised, phase 2b trial.
van Lunzen J, Maggiolo F, Arribas JR,
et
al
Lancet Infect Dis.
2011 Oct 20
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Dolutegravir (S/GSK1349572) Exhibits Significantly
Slower Dissociation than Raltegravir and Elvitegravir from
Wild Type
and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes.
Hightower KE, Wang R, Deanda F, et al
Antimicrob Agents Chemother.
2011 Aug 1.
Abstract
-
Structural and Functional Analyses of the
Second-generation Integrase Strand Transfer Inhibitor
Dolutegravir (S/GSK1349572).
Hare S, Smith SJ, Metifiot M, Jaxa-Chamiec A,
et al
Mol Pharmacol. 2011 Jun 30
Abstract
-
A WEEK-IN-REVIEW FEATURED
REPORT
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of
dolutegravir as
10-day monotherapy
in HIV-1-infected adults.
Min S, Sloan L, Dejesus E, Hawkins T, et al
AIDS.
2011 Jun 29
Abstract
-
'A WEEK-IN-REVIEW FEATURED REPORT
The Effect of Etravirine Alone and with Ritonavir-Boosted Protease
Inhibitors on the Pharmacokinetics
of Dolutegravir.
Song I, Borland J, Min S, et al
Antimicrob Agents Chemother.
2011 May
Abstract
-
Pharmacokinetics of the HIV integrase inhibitor
S/GSK1349572 co-administered with acid-reducing agents
and
multivitamins in healthy volunteers.
Patel P, Song I, Borland J,
et al
J Antimicrob Chemother.
2011 Apr 14
Abstract
-
Prevalence of resistance mutations related to integrase inhibitor
S/GSK1349572 in HIV-1
subtype B raltegravir-naive and -treated patients.
Malet I, Wirden M, Fourati S, et al
J Antimicrob Chemother. 2011
Apr
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
S/GSK1349572, a new integrase inhibitor for the
treatment of HIV: promises and challenges.
Lenz JC, Rockstroh JK.
Expert Opin Investig Drugs. 2011 Mar 8.
Abstract
-
Effect of Atazanavir and Atazanavir/Ritonavir on the
Pharmacokinetics of the Next-Generation
HIV Integrase Inhibitor, S/GSK1349572.
Song I, Borland J, Chen S,
Br J Clin Pharmacol.
2011 Feb 22.
Abstract
-
In Vitro Virology of S/GSK1349572, a Next-Generation
HIV Integrase Inhibitor.
Kobayashi M, Yoshinaga T, Seki T, et al
Antimicrob Agents Chemother.
2010 Nov 29
Abstract
-
Lack of interaction between the HIV integrase inhibitor
S/GSK1349572 and tenofovir in healthy subjects.
Song I, Min SS, Borland J, et al
J Acquir Immune Defic Syndr.
2010 Nov 1;55(3):365-7.
Abstract
-
The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase
Inhibitor
S/GSK1349572 in Healthy Participants.
Song I, Min SS, Borland J, et al
J Clin Pharmacol. 2010
May 20.
Abstract
- A WEEK-IN-REVIEW
FEATURED REPORT
FULL-TEXT ARTICLE
First
Mutations in S/GSK1349572 Resistance Pathway May Arise Before
Integrase
Inhibitor Therapy
Mascolini, M
Medadvocates Web Feb 2010
Paper
-
FULL-TEXT ARTICLE
Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase
inhibitor,
in healthy volunteers.
Min S,
Song I,
Borland J,
Chen S,
Lou Y,
Antimicrob Agents Chemother. 2010 Jan;54(1):254-8
Paper
|
|
19 CROI
|
-
POSTER
Antiviral Activity
in vitro of the INI, Dolutegravir, against Raltegravir-resistant HIV-2
Mutants
Mi Kobayashi, T Seki T
Yoshinaga, et al
PDF Poster
Abstract
|
6th IAS Conference
|
-
Increasing patient
compliance in SPRING-1 phase IIb HIV clinical trial in ART-naïve patients
with dolutegravir (DTG, S/GSK1349572)
J. Harris, S. Hughes, C. Brothers
Abstract
-
Rapid, robust and
sustained antiviral response with once-daily (QD) dolutegravir (DTG,
S/GSK1349572), a next generation integrase inhibitor (INI) in combination
therapy in antiretroviral-naïve adults: 48 week results from SPRING-1
(ING112276)
J. Van Lunzen, F. Maggiolo, B. Phung, et al
Abstract
-
No impact of HIV
integrase polymorphisms at position 101 and 124 on in vitro resistance
isolation with dolutegravir (DTG, S/GSK1349572), a potent next generation
HIV integrase inhibitor
T. Seki, S. Miki, M. Kobayashi, T. Yoshinaga
Abstract
-
Safety profile of
dolutegravir (DTG, S/GSK1349572), in combination with other antiretrovirals
in antiretroviral (ART)-naïve and ART-experienced adults from two phase IIb
studies
S. Min, A. Carrod, L. Curtis, C. Stainsby
Abstract
|
17th CROI
-
POSTER
Resistance-associated Mutations to Integrase Inhibitor S/GSK1349572
in HIV-1 Integrase
Inhibitor-naive and Raltegravir-experienced Patients
A-G Marcelin, I Malet,
L Fabeni, et al
PDF Poster
Abstract
-
POSTER
S/GSK1349572 Is a Potent Next Generation HIV Integrase Inhibitor
and Demonstrates a
Superior Resistance Profile Substantiated with 60 Integrase Mutant
Molecular Clones
T Sek, M Kobayashi, C Wakasa-Morimoto.
et al
PDF
Poster
Abstract
|
|
|
Dolutegravir
(S/GSK139572)
|
|
New
and Noteworthy
ARV
Investigational Drugs Main Page